The committee voted. It didn't rubber-stamp.

Back in June we flagged a meeting worth watching. The FDA's Pharmacy Compounding Advisory Committee was set to take up seven of the most-discussed peptides and decide whether to recommend them for the 503A bulks list, the roster of substances licensed pharmacies are allowed to compound. The meeting happened on July 23 and 24. The votes are in.

Six of the seven got a favorable recommendation. One did not. That one-line result is accurate and almost useless, because the interesting part is where the committee said no, and how narrowly it said yes in a couple of cases.

What the vote actually was

The four peptides taken up on Thursday all cleared: BPC-157, KPV, TB-500, and MOTS-c. On Friday the committee recommended Semax and Epitalon as well. The Epitalon vote came with a wrinkle. It wasn't a blanket endorsement but a recommendation tied to a specific use, insomnia, and it passed by a slim margin with an abstention. A recommendation with an indication attached and a 5-vote spread is a different animal from a unanimous yes.

The one that didn't make it was emideltide, the peptide most people know as DSIP, the delta sleep-inducing peptide. It lost in a near-tie. If you've read the explainer here on what DSIP actually is, you know the human evidence for it is thin and old. The committee, looking at the same picture, declined to recommend it.

Why the "no" is the story

It would have been easy to read this meeting as a formality. The FDA had already cleared BPC-157 out of the safety-question category in April, the political weather around compounded peptides had shifted toward access, and seven nominations were on the table. A committee that was going to wave everything through would have waved everything through.

It didn't. It turned one peptide down and it hedged on another. That tells you the members were actually weighing the files rather than reading demand off a forum. Two of the seven touch sleep, DSIP and the insomnia use for Epitalon, and the committee split them: one recommended, one rejected. Reasonable people can argue about whether they drew that particular line in the right place. The point is that a line got drawn at all.

A recommendation is still not a verdict

We made this point in June and it survives the vote unchanged, so hold onto it. A favorable recommendation is advisory. The committee doesn't add anything to anything. The FDA takes the recommendations, then decides on its own, and any actual change to the bulks list runs through formal rulemaking that hasn't happened yet. Nothing about what you can legally get from a pharmacy changed this week.

And permission to compound is a statement about manufacturing oversight and acceptable risk, not a grade on whether the compound works. A peptide can clear this bar and still have almost no controlled human data behind the use people actually want it for. That gap doesn't close because a committee voted. It's the same gap it was in June.

How to hold it

Two clocks, still running at different speeds. The regulatory clock moved this week: a vote, a set of recommendations, more process to come. The evidence clock didn't move at all, because votes aren't trials. When those two get out of sync, the honest read isn't "it passed, so it must be good," and it isn't "it got rejected, so it must be worthless." DSIP didn't get less studied because the committee said no, and BPC-157 didn't get better studied because it said yes.

What actually happened is narrower and more encouraging than either headline. A group of people looked at seven files, recommended six, rejected one, and attached conditions where they thought conditions belonged. That's a committee doing its job on thin evidence, which is roughly what you'd want. The homework is still due. At least someone read the assignments.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.